株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

抗体薬物複合体(ADC):技術および世界市場

Antibody Drug Conjugates: Technologies and Global Markets

発行 BCC Research 商品コード 296130
出版日 ページ情報 英文 132 Pages
即納可能
価格
本日の銀行送金レート: 1USD=110.74円で換算しております。
Back to Top
抗体薬物複合体(ADC):技術および世界市場 Antibody Drug Conjugates: Technologies and Global Markets
出版日: 2017年06月30日 ページ情報: 英文 132 Pages
担当者のコメント
BCC Research社のレポートは、Reuter、Wall Street Journal、Fortuneなどで引用されることも多く、それぞれの業界の識者の意見として重きを置かれています。同社レポートを複数冊ご購入の場合年間パッケージのご契約がお得です。詳細は右の担当者のおすすめ商品よりご覧下さい。
概要

抗体薬物複合体(ADC)の世界市場は、2016年の13億米ドルから25.5%の複合年間成長率(CAGR)で2021年までに42億米ドル規模に拡大することが見込まれています。

当レポートでは、抗体薬物複合体(ADC)の世界市場について調査し、抗体薬物複合体の技術概要、産業構造、技術・用途・標的抗原・地域別の市場動向、市場規模・成長率の推移と今後の予測、市場促進要因ならびに課題、特許概要、競合情勢、主要企業のプロファイルなど、体系的な情報を提供しています。

第1章 イントロダクション

第2章 調査の要旨

第3章 市場動向・技術背景

  • 定義
  • 抗体薬物複合体(ADC)の構成要素
  • 抗体薬物複合体(ADC)の仕組み
  • 歴史的視点
  • 抗体薬物複合体(ADC)の利点
  • 認証済み抗体薬物複合体(ADC)
    • Mylotarg
    • Adcetris
    • Kadcyla
  • 抗体薬物複合体(ADC)技術
  • 主な抗体薬物複合体(ADC)の標的
    • CD19
    • CD20
    • CD22
    • CD25
    • CD30
    • CD33
    • CD40
    • CD56
    • CD74
    • CD70a、CD79b
    • CD138
    • CEACAM
    • EGFR
    • EGP-1
    • GPNMB
    • HER2
    • LIV-1
    • Mesothelin
    • Nectin-4
    • SLITRK6
    • VEGF
  • モノクローナル抗体の種類
  • 低分子薬剤の種類
  • リンカーの種類
  • 薬物複合技術
    • 従来の複合技術
    • 局所的複合技術

第4章 抗体薬物複合体(ADC)の世界市場:技術別

  • 抗体薬物複合体(ADC)の世界市場:低分子薬別
  • 抗体薬物複合体(ADC)の世界市場:モノクローナル抗体別
  • 抗体薬物複合体(ADC)の世界市場:リンカー別

第5章 抗体薬物複合体(ADC)の世界市場:用途別

  • 抗体薬物複合体(ADC)の世界市場:癌治療別
    • 市場シェア
    • 乳癌
    • 悪性リンパ腫
    • その他の癌

第6章 産業構造

  • マーケットリーダー
  • 市場シェア

第7章 抗体薬物複合体(ADC)の世界市場:地域別

  • 市場概要
  • 収益
  • 抗体薬物複合体(ADC)の世界市場:標的抗原別

第8章 特許概要・近年の動向

  • 特許分析
  • 近年の動向
  • 規制上の問題

第9章 市場機会の分析

  • 市場促進要因
  • 市場の課題
  • 生産戦略

第10章 企業プロファイル

付録:略語一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: PHM161B

The global market for antibody drug conjugates was valued at $1.3 billion in 2016. The market should reach $4.2 billion by 2021, growing at a compound annual growth rate (CAGR) of 25.5% from 2016 to 2021

Report Includes

  • An overview of the global market for antibody drug conjugates as a part of the pharmaceutical industry that is looking for innovative technologies.
  • Analyses of global market trends, with data from 2014, 2015 and 2016, and projections of compound annual growth rates (CAGRs) through 2021.
  • Examination of key market drivers and challenges.
  • Insight into regulatory hurdles and how to meet them, as well as discussion of the drugs (and the companies behind them) that have received approval.

Report Scope

Antibody drug conjugates are mainly used to treat cancer and are safer and more effective than many other cancer therapies. This report focuses on the global market for antibody drug conjugate products and provides an updated review, including their basic design and application in various areas of the biomedical sciences. The report covers three main areas of application, breast cancer, lymphoma and other cancers, including acute myeloid leukemia. The scope of this study includes the current market for ADCs. The report also discusses regulatory aspects, current and developing technologies, market projections and market shares. An analysis of clinical trials, innovations and opportunities and the latest trends in ADC market are also discussed in the report.

Also included in the report is an analysis of relevant patents and profiles of companies that lead the antibody drug conjugate product market. Seattle Genetics Inc., Takeda Pharmaceuticals Co. Ltd. and Genentech Inc. are the major players in the market for ADCs at present.

Sales data for the global and regional markets were corroborated for the present and forecasted values via statistical analysis, and sales are broken down geographically into North America, Europe, Asia-Pacific and the emerging markets. The application of ADCs in various types of cancer is discussed from both a commercial perspective and that of a research and development (R&D) perspective.

The report only covers antibody drug conjugates in which an antibody is conjugated with small-molecule cytotoxins (payload) through a linker. ADCs are a form of antibody conjugates. Other forms of antibody conjugates such as radioisotope conjugated with an antibody are beyond the scope of this report. The study also does not cover mAbs that do not contain a linker and cytotoxic agent and, thus, do not constitute an ADC.

Analyst Credentials

SHALINI DEWAN focuses on pharmaceuticals and biotechnology and has been a BCC Research contributor since 2002 as both an analyst and project manager. She has explored a wide range of topics and companies, including working for Johnson & Johnson doing market surveillance. She has an undergraduate degree in pharmacy and master's degree in medicinal chemistry. She resides in the Bay Area.

Table of Contents

Chapter 1: Introduction

  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of Report
  • Information Sources
  • Methodology
  • Geographic Breakdown
  • Analyst's Credentials
  • Related BCC Research Reports.

Chapter 2: Summary and Highlights

Chapter 3: Market and Technology Background

  • Definitions
  • Components of ADCs
  • How ADCs Work
  • Historical Perspective.
  • Advantages of ADCs
  • Approved ADCs
    • Mylotarg (Gemtuzumab Ozogamicin)
    • Adcetris (Brentuximab Vedotin)
    • Kadcyla (Trastuzumab-DM1)
  • Antibody Drug Conjugation Technologies
  • Key ADC Targets
    • CD19
    • CD20
    • CD22
    • CD25
    • CD30
    • CD33
    • CD40
    • CD56
    • CD74
    • CD79a and CD79b
    • CD138 (Syndecan-1)
    • CEACAM (Carcinoembryonic Antigen-Related Cell Adhesion Molecule)
    • EGFR (Epidermal Growth Factor Receptor/ERBB1)
    • EGP-1 (Epithelial Glycoprotein-1 Antigen)
    • GPNMB
    • HER2 (Human Epidermal Growth Factor Receptor)
    • LIV-1
    • Mesothelin
    • Nectin-4
    • Prostate-Specific Membrane Antigen (PSMA)
    • SLITRK6
    • VEGF (Vascular Endothelial Growth Factor)
  • Types of Monoclonal Antibodies
  • Types of Payloads (Cytotoxic Agents)
  • Types of Linkers.
  • Conjugation Methods
    • Conventional Conjugation Method
    • Site-Specific Conjugation

Chapter 4: Market Breakdown by Technology Type

  • Market for ADCs by Type of Payload
    • Market Overview
    • Market Revenues
  • Market for ADCs by Type of Monoclonal Antibody
    • Market Overview
    • Market Revenues
  • Market for ADCs by Type of Linker
    • Market Overview
    • Market Revenues

Chapter 5: Market Breakdown by Application

  • Global Market for the Application of ADCs in Treating Various Types of Cancers
    • Market Share
    • Breast Cancer
    • Lymphoma
    • Other Types of Cancer

Chapter 6: Industry Structure

  • Market Leaders
  • Market Share

Chapter 7: Market Breakdown by Region

  • Market Overview
  • Market Revenues
  • Market for ADCs by Target Antigen
    • Market for CD-30 Targeting ADCs
    • Market for HER2 Targeting ADCs
    • Market for Other Antigen Targeting ADCs

Chapter 8: Patent Review/New Developments

  • Patent Analysis
    • Patents by Year
    • Patents by Company
    • Patents by Country
    • Patents by Assignee
  • New Developments
    • CMC-544
    • CDX-011
    • RG7596 (Polatuzumab Vedotin)
    • RG7593 (Pinatuzumab Vedotin)
    • PSMA ADC
    • IMGN853 (Mirvetuximab Soravtansine)
    • BT-062
  • Regulatory Issues
    • Regulatory History of Approved ADCs
    • Regulatory Exclusivity
    • Other Regulatory Issues

Chapter 9: Analysis of Market Opportunities

  • Key Drivers
    • Patent Expiration
    • Targeted Nature of ADCs
    • Complexity of ADCs
    • Investor Confidence in Biologics
    • Increased Research on ADC Development
    • Other Factors
  • Key Challenges
  • Manufacturer Strategies

Chapter 10: Company Profiles

Appendix: Abbreviations

About BCC Research

  • About BCC Research.
  • BCC Membership
  • BCC Custom Research

List of Tables

  • Summary Table: Global Market for Antibody Drug Conjugates, by Region, Through 2021 ($ Millions)
  • Table 1 History of Antibody Drug
  • Table 2 Types of Antibody Drug Conjugates Based on Type of Monoclonal Antibody
  • Table 3 Significant Antibody Drug Conjugate Payloads
  • Table 4 Significant Antibody Drug Conjugate Linkers
  • Table 5 Commercially Available Antibody Drug Conjugates: Key Components and Target Antigens
  • Table 6 Antibody Drug Conjugates with Significant Market Potential During the Forecast Period
  • Table 7 Global Market for Antibody Drug Conjugates, by Type of Payload, Through 2021 ($ Millions)
  • Table 8 Global Market for Antibody Drug Conjugates, by Type of mAb, Through 2021 ($ Millions)
  • Table 9 Global Market for Antibody Drug Conjugates, by Type of Linker, Through 2021 ($ Millions)
  • Table 10 Global Market for Antibody Drug Conjugates, by Type of Cancer, Through 2021 ($ Millions)
  • Table 11 Global Market Shares of Antibody Drug Conjugates, by Type of Cancer, 2016 (%)
  • Table 12 Global Market for Breast Cancer Antibody Drug Conjugates, by Region, Through 2021 ($ Millions)
  • Table 13 Global Market for Lymphoma Antibody Drug Conjugates, by Region, Through 2021 ($ Millions)
  • Table 14 Global Market for Other Types of Antibody Drug Conjugates, by Region, Through 2021 ($ Millions)
  • Table 15 Leading Manufacturers/Suppliers of Antibody Drug Conjugates, 2016
  • Table 16 Global Market Shares of Manufacturers/Suppliers for Antibody Drug Conjugates, 2016 (%)
  • Table 17 Global Market for Antibody Drug Conjugates, by Region, Through 2021 ($ Millions)
  • Table 18 Significant Early Stage Clinical Trials on Adcetris, 2017
  • Table 19 Global Market for CD30 Targeting Antibody Drug Conjugates, by Region, Through 2021 ($ Millions)
  • Table 20 Significant Early Stage Clinical Trials on Kadcyla, 2017
  • Table 21 Global Market for HER2 Targeting Antibody Drug Conjugates, by Region, Through 2021 ($ Millions)
  • Table 22 Global Market for Other Types of Targeting Antibody Drug Conjugates, by Region, Through 2021 ($ Millions)
  • Table 23 Number of U.S. Patents on ADCs Issued by Year, 2013 Through Feb.2017
  • Table 24 Number of U.S. Patents on ADCs Held by Company, 2013 Through Feb.2017
  • Table 25 Number of U.S. Patents on ADCs by Assignee's Country, 2013 Through Feb.2017
  • Table 26 U.S. Patent Shares of ADCs by Assignee's Country, 2013 Through Feb.2017 (No./%)
  • Table 27 Number of U.S. Patents on ADCs by Type of Assignee, 2013 Through Feb.2017
  • Table 28 Number of Investigational New Drug Applications Filed, 2003-2016
  • Table 29 ADCs in Research Pipeline as of Feb.9992017
  • Table 30 Orphan Drug Designations Granted for Adcetris
  • Table 31 Major Alliances for ADC Development
  • Table 32 Abbreviations Used in Antibody Drug Conjugates

List of Figures

  • Summary Figure: Global Market for Antibody Drug Conjugates, by Region, 2014-2021 ($ Millions)
  • Figure 1 Global Market for Antibody Drug Conjugates, by Type of Payload, 2014-2021 ($ Millions)
  • Figure 2 Global Market for Antibody Drug Conjugates, by Type of mAb, 2014-2021 ($ Millions)
  • Figure 3 Global Market for Antibody Drug Conjugates, by Type of Linker, 2014-2021 ($ Millions)
  • Figure 4 Global Market for Antibody Drug Conjugates, by Type of Cancer, 2014-2021 ($ Millions)
  • Figure 5 Global Market Shares of Antibody Drug Conjugates, by Type of Cancer, 2016 (%)
  • Figure 6 Global Market for Breast Cancer Antibody Drug Conjugates, by Region, 2014-2021 ($ Millions)
  • Figure 7 Global Market for Lymphoma Antibody Drug Conjugates, by Region, 2014-2021 ($ Millions)
  • Figure 8 Global Market for Other Types of Antibody Drug Conjugates, by Region, 2014-2021 ($ Millions)
  • Figure 9 Global Market Shares of Manufacturers/Suppliers of Antibody Drug Conjugates, 2016 (%)
  • Figure 10 Global Market for Antibody Drug Conjugates, by Region, 2014-2021 ($ Millions)
  • Figure 11 Global Market for CD30 Targeting Antibody Drug Conjugates, by Region, 2014-2021 ($ Millions)
  • Figure 12 Global Market for HER2 Targeting Antibody Drug Conjugates, by Region, 2014-2021 ($ Millions)
  • Figure 13 Global Market for Other Types of Targeting Antibody Drug Conjugates, by Region, 2014-2021 ($ Millions)
  • Figure 14 Number of U.S. Patents on ADCs Issued by Year, 2013 Through Feb.2017
  • Figure 15 Number of U.S. Patents on ADCs Held by Company, 2013 Through Feb.2017
  • Figure 16 Number of U.S. Patents on ADCs by Assignee's Country, 2013 Through Feb.2017
  • Figure 17 U.S. Patent Shares of ADCs by Assignee's Country, 2013 Through Feb.2017 (%)
  • Figure 18 Number of U.S. Patents on ADCs by Type of Assignee, 2013 Through Feb.2017
Back to Top